| 1. |
|
|
| 2. |
- Reifarth, R., et al.
(författare)
-
Nuclear astrophysics with radioactive ions at FAIR
- 2016
-
Ingår i: Journal of Physics: Conference Series. - : IOP Publishing. - 1742-6588 .- 1742-6596. ; 665:1
-
Konferensbidrag (refereegranskat)abstract
- The nucleosynthesis of elements beyond iron is dominated by neutron captures in the s and r processes. However, 32 stable, proton-rich isotopes cannot be formed during those processes, because they are shielded from the s-process flow and r-process beta-decay chains. These nuclei are attributed to the p and rp process. For all those processes, current research in nuclear astrophysics addresses the need for more precise reaction data involving radioactive isotopes. Depending on the particular reaction, direct or inverse kinematics, forward or time-reversed direction are investigated to determine or at least to constrain the desired reaction cross sections. The Facility for Antiproton and Ion Research (FAIR) will offer unique, unprecedented opportunities to investigate many of the important reactions. The high yield of radioactive isotopes, even far away from the valley of stability, allows the investigation of isotopes involved in processes as exotic as the r or rp processes.
|
|
| 3. |
- Krasznahorkay, A., et al.
(författare)
-
Neutron-skin thickness from the study of the anti-analog giant dipole resonance
- 2012
-
Ingår i: AIP Conference Proceedings. - : AIP. - 1551-7616 .- 0094-243X. - 9780735411036 ; 1491, s. 190-197
-
Konferensbidrag (refereegranskat)abstract
- The γ-decay of the anti-analog of the giant dipole resonance (AGDR) to the isobaric analog state has been measured following the p( 124Sn,n) reaction at a beam energy of 600 MeV/nucleon. The energy of the transition was also calculated with state-of-the-art self-consistent relativistic random-phase approximation (RPA) and turned out to be very sensitive to the neutronskin thickness (ΔRpn). By comparing the theoretical results with the measured one, the ΔRpn value for 124Sn was deduced to be 0.21 ± 0.07 fm, which agrees well with the previous results. The present method offers new possibilities for measuring the neutron-skin thicknesses of very exotic isotopes.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Siva, D, et al.
(författare)
-
Mollification of Doxorubicin (DOX)-Mediated Cardiotoxicity Using Conjugated Chitosan Nanoparticles with Supplementation of Propionic Acid
- 2022
-
Ingår i: Nanomaterials (Basel, Switzerland). - : MDPI AG. - 2079-4991. ; 12:3
-
Tidskriftsartikel (refereegranskat)abstract
- Doxorubicin is an extensively prescribed antineoplastic agent. It is also known for adverse effects, among which cardiotoxicity tops the list. The possible mechanism underlying doxorubicin (DOX)-mediated cardiotoxicity has been investigated in this study. Further, to reduce the DOX-mediated cardiotoxicity, DOX was conjugated with Chitosan Nanoparticles (DCNPs) and supplemented with propionic acid. Initially, the drug loading efficacy and conjugation of DOX with chitosan was confirmed by UV–Visible Spectroscopy (UV) and Fourier Transform Infrared Spectroscopy (FTIR). The average sizes of the synthesized Chitosan Nanoparticles (CNPs) and DCNPs were measured by Dynamic Light Scattering (DLS) analysis as 187.9 ± 1.05 nm and 277.3 ± 8.15 nm, respectively, and the zeta potential values were recorded as 55.2 ± 0.7 mV and 51.9 ± 1.0 mV, respectively. The size and shape of CNPs and DCNPs were recorded using a High-Resolution Electron Microscopy (HRTEM). The particles measured <30 nm and 33–84 nm, respectively. The toxic effects of DCNPs and propionic acid were evaluated in rat model. The data from the electrocardiogram (ECG), cardiac biomarkers, Peroxisome proliferator-activated receptor gamma (PPARγ) and histological observations indicated evidence of DOX-mediated cardiotoxicity, whereas the administration of DCNPs, as well as Propionic Acid (PA), brought about a restoration to normalcy and offered protection in the context of DOX-induced cardiotoxicity.
|
|
| 10. |
- Todde, Sergio, et al.
(författare)
-
EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)
- 2014
-
Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer Verlag (Germany). - 1619-7070 .- 1619-7089. ; 41:11, s. 2175-2185
-
Tidskriftsartikel (refereegranskat)abstract
- The preparation of an Investigational Medicinal Product Dossier (IMPD) for a radiopharmaceutical to be used in a clinical trial is a challenging proposition for radiopharmaceutical scientists working in small-scale radiopharmacies. In addition to the vast quantity of information to be assembled, the structure of a standard IMPD is not well suited to the special characteristics of radiopharmaceuticals. This guideline aims to take radiopharmaceutical scientists through the practicalities of preparing an IMPD, in particular giving advice where the standard format is not suitable. Examples of generic IMPDs for three classes of radiopharmaceuticals are given: a small molecule, a kit-based diagnostic test and a therapeutic radiopharmaceutical.
|
|
